Acetyl-l-carnitine and lipoic acid improve mitochondrial abnormalities and serum levels of liver enzymes in a mouse model of nonalcoholic fatty liver disease

Nutrition Research

Volumn 33, Issue 11, 2013, Pages 932-941

  Kathirvel, Elango ^a   Morgan, Kengathevy ^a   French, Samuel W ^c,d   Morgan, Timothy R ^a,b  

^a VA LONG BEACH HEALTHCARE SYSTEM   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c HARBOR UCLA MEDICAL CENTER   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Acetyl L carnitine; High fat diet; Lipoic acid; Mitochondria; Mouse; Nonalcoholic fatty liver; Oxidative stress

Indexed keywords

ALANINE AMINOTRANSFERASE; ANTIOXIDANT; ASPARTATE AMINOTRANSFERASE; CARBAMOYL PHOSPHATE SYNTHASE; GLUCOSE; INSULIN; LEVACECARNINE PLUS THIOCTIC ACID; LIVER ENZYME; MALONALDEHYDE; UNCLASSIFIED DRUG;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIOXIDANT ACTIVITY; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BODY WEIGHT; CELLULAR DISTRIBUTION; CONTROLLED STUDY; DISORDERS OF MITOCHONDRIAL FUNCTIONS; ELECTRON MICROSCOPY; ENZYME BLOOD LEVEL; FATTY LIVER; GLUCOSE BLOOD LEVEL; GLUCOSE TOLERANCE; HISTOPATHOLOGY; INFLAMMATION; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; LIPID PEROXIDATION; LIPID STORAGE; LIVER FUNCTION; LIVER MITOCHONDRION; LIVER WEIGHT; MALE; MITOCHONDRIAL VOLUME; MOUSE; NONALCOHOLIC FATTY LIVER; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN LOCALIZATION; WHITE ADIPOSE TISSUE;

ANIMALIA; MUS; RODENTIA;

ACETYL-L-CARNITINE; ALANINE AMINOTRANSFERASE; ALC; ALT; ASPARTATE AMINOTRANSFERASE; AST; BOVINE SERUM ALBUMIN; BSA; CABAMOYL PHOSPHATE SYNTHASE 1; COA; COENZYME A; CPS-1; H&E; HEMATOXYLIN AND EOSIN; HF; HIGH FAT; HIGH FAT DIET; LA; LIPOIC ACID; MALONDIALDEHYDE; MDA; MITOCHONDRIA; MOUSE; NAFLD; NASH; NONALCOHOLIC FATTY LIVER; NONALCOHOLIC FATTY LIVER DISEASE; NONALCOHOLIC STEATOHEPATITIS; OXIDATIVE STRESS; SF; STANDARD FAT; WAT; WHITE ADIPOSE TISSUE;

ACETYLCARNITINE; ADIPOSE TISSUE; ALANINE TRANSAMINASE; ANIMALS; ANTIOXIDANTS; ASPARTATE AMINOTRANSFERASES; BODY WEIGHT; DIET, HIGH-FAT; DISEASE MODELS, ANIMAL; FATTY LIVER; INSULIN RESISTANCE; LIVER; MALE; MICE; MICE, INBRED BALB C; MITOCHONDRIA; ORGAN SIZE; OXIDATIVE STRESS; THIOCTIC ACID;

EID: 84886397319     PISSN: 02715317     EISSN: 18790739     Source Type: Journal    
DOI: 10.1016/j.nutres.2013.08.001     Document Type: Article

References (43)

1. Falck-Ytter Y., Younossi Z.M., Marchesini G., McCullough A.J. Clinical features and natural history of nonalcoholic steatosis syndromes. Semin Liver Dis 2001, 21:17-26.
2. Preiss D., Sattar N. Non-alcoholic fatty liver disease: an overview of prevalence, diagnosis, pathogenesis and treatment considerations. Clin Sci (Lond) 2008, 115:141-150.
3. Sanyal A.J., Chalasani N., Kowdley K.V., McCullough A., Diehl A.M., Bass N.M., et al. Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. N Engl J Med 2010, 362:1675-1685.
4. Kathirvel E., Morgan K., Nandgiri G., Sandoval B.C., Caudill M.A., Bottiglieri T., et al. Betaine improves nonalcoholic fatty liver and associated hepatic insulin resistance: a potential mechanism for hepatoprotection by betaine. Am J Physiol Gastrointest Liver Physiol 2010, 299:G1068-G1077.
5. Song Z., Deaciuc I., Zhou Z., Song M., Chen T., Hill D., et al. Involvement of AMP-activated protein kinase in beneficial effects of betaine on high-sucrose diet-induced hepatic steatosis. Am J Physiol Gastrointest Liver Physiol 2007, 293:G894-G902.
6. Wei Y., Rector R.S., Thyfault J.P., Ibdah J.A. Nonalcoholic fatty liver disease and mitochondrial dysfunction. World J Gastroenterol 2008, 14:193-199.
7. Begriche K., Igoudjil A., Pessayre D., Fromenty B. Mitochondrial dysfunction in NASH: causes, consequences and possible means to prevent it. Mitochondrion 2006, 6:1-28.
8. Perez-Carreras M., Del Hoyo P., Martin M.A., Rubio J.C., Martin A., Castellano G., et al. Defective hepatic mitochondrial respiratory chain in patients with nonalcoholic steatohepatitis. Hepatology 2003, 38:999-1007.
9. Robertson G., Leclercq I., Farrell G.C. Nonalcoholic steatosis and steatohepatitis. II. Cytochrome P-450 enzymes and oxidative stress. Am J Physiol Gastrointest Liver Physiol 2001, 281:G1135-G1139.
10. Lieber C.S. CYP2E1: from ASH to NASH. Hepatol Res 2004, 28:1-11.
11. Morgan K., French S.W., Morgan T.R. Production of a cytochrome P450 2E1 transgenic mouse and initial evaluation of alcoholic liver damage. Hepatology 2002, 36:122-134.
12. Polavarapu R., Spitz D.R., Sim J.E., Follansbee M.H., Oberley L.W., Rahemtulla A., et al. Increased lipid peroxidation and impaired antioxidant enzyme function is associated with pathological liver injury in experimental alcoholic liver disease in rats fed diets high in corn oil and fish oil. Hepatology 1998, 27:1317-1323.
13. Kathirvel E., Chen P., Morgan K., French S.W., Morgan T.R. Oxidative stress and regulation of anti-oxidant enzymes in cytochrome P4502E1 transgenic mouse model of non-alcoholic fatty liver. J Gastroenterol Hepatol 2010, 25:1136-1143.
14. Roberts C.K., Barnard R.J., Sindhu R.K., Jurczak M., Ehdaie A., Vaziri N.D. Oxidative stress and dysregulation of NAD(P)H oxidase and antioxidant enzymes in diet-induced metabolic syndrome. Metabolism 2006, 55:928-934.
15. Rebouche C.J. Carnitine function and requirements during the life cycle. FASEB J 1992, 6:3379-3386.
16. Hagen T.M., Liu J., Lykkesfeldt J., Wehr C.M., Ingersoll R.T., Vinarsky V., et al. Feeding acetyl-L-carnitine and lipoic acid to old rats significantly improves metabolic function while decreasing oxidative stress. Proc Natl Acad Sci U S A 2002, 99:1870-1875.
17. Hagen T.M., Ingersoll R.T., Wehr C.M., Lykkesfeldt J., Vinarsky V., Bartholomew J.C., et al. Acetyl-L-carnitine fed to old rats partially restores mitochondrial function and ambulatory activity. Proc Natl Acad Sci U S A 1998, 95:9562-9566.
18. Liu J., Head E., Gharib A.M., Yuan W., Ingersoll R.T., Hagen T.M., et al. Memory loss in old rats is associated with brain mitochondrial decay and RNA/DNA oxidation: partial reversal by feeding acetyl-L-carnitine and/or R-alpha -lipoic acid. Proc Natl Acad Sci U S A 2002, 99:2356-2361.
19. Hagen T.M., Ingersoll R.T., Lykkesfeldt J., Liu J., Wehr C.M., Vinarsky V., et al. (R)-alpha-lipoic acid-supplemented old rats have improved mitochondrial function, decreased oxidative damage, and increased metabolic rate. FASEB J 1999, 13:411-418.
20. Malaguarnera M. Carnitine derivatives: clinical usefulness. Curr Opin Gastroenterol 2012, 28:166-176.
21. Bowyer B.A., Miles J.M., Haymond M.W., Fleming C.R. L-carnitine therapy in home parenteral nutrition patients with abnormal liver tests and low plasma carnitine concentrations. Gastroenterology 1988, 94:434-438.
22. Malaguarnera M., Gargante M.P., Russo C., Antic T., Vacante M., Avitabile T., et al. L-carnitine supplementation to diet: a new tool in treatment of nonalcoholic steatohepatitis-a randomized and controlled clinical trial. Am J Gastroenterol 2010, 105:1338-1345.
23. Christie L.A., Opii W.O., Head E., Araujo J.A., de Rivera C., Milgram N.W., et al. Short-term supplementation with acetyl-L-carnitine and lipoic acid alters plasma protein carbonyl levels but does not improve cognition in aged beagles. Exp Gerontol 2009, 44:752-759.
24. Suchy J., Chan A., Shea T.B. Dietary supplementation with a combination of alpha-lipoic acid, acetyl-L-carnitine, glycerophosphocoline, docosahexaenoic acid, and phosphatidylserine reduces oxidative damage to murine brain and improves cognitive performance. Nutr Res 2009, 29:70-74.
25. Aliev G., Liu J., Shenk J.C., Fischbach K., Pacheco G.J., Chen S.G., et al. Neuronal mitochondrial amelioration by feeding acetyl-L-carnitine and lipoic acid to aged rats. J Cell Mol Med 2009, 13:320-333.
26. Bachmanov A.A., Reed D.R., Beauchamp G.K., Tordoff M.G. Food intake, water intake, and drinking spout side preference of 28 mouse strains. Behav Genet 2002, 32:435-443.
27. Morgan K., Uyuni A., Nandgiri G., Mao L., Castaneda L., Kathirvel E., et al. Altered expression of transcription factors and genes regulating lipogenesis in liver and adipose tissue of mice with high fat diet-induced obesity and nonalcoholic fatty liver disease. Eur J Gastroenterol Hepatol 2008, 20:843-854.
28. French S.W., Ruebner B.H., Mezey E., Tamura T., Halsted C.H. Effect of chronic ethanol feeding on hepatic mitochondria in the monkey. Hepatology 1983, 3:34-40.
29. Liu J., Yeo H.C., Doniger S.J., Ames B.N. Assay of aldehydes from lipid peroxidation: gas chromatography-mass spectrometry compared to thiobarbituric acid. Anal Biochem 1997, 245:161-166.
30. Laemmli U.K. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 1970, 227:680-685.
31. Thyfault J.P., Rector R.S., Uptergrove G.M., Borengasser S.J., Morris E.M., Wei Y., et al. Rats selectively bred for low aerobic capacity have reduced hepatic mitochondrial oxidative capacity and susceptibility to hepatic steatosis and injury. J Physiol 2009, 587:1805-1816.
32. Rector R.S., Thyfault J.P., Uptergrove G.M., Morris E.M., Naples S.P., Borengasser S.J., et al. Mitochondrial dysfunction precedes insulin resistance and hepatic steatosis and contributes to the natural history of non-alcoholic fatty liver disease in an obese rodent model. J Hepatol 2010, 52:727-736.
33. Crouser E.D., Julian M.W., Huff J.E., Struck J., Cook C.H. Carbamoyl phosphate synthase-1: a marker of mitochondrial damage and depletion in the liver during sepsis. Crit Care Med 2006, 34:2439-2446.
34. Jun D.W., Cho W.K., Jun J.H., Kwon H.J., Jang K.S., Kim H.J., et al. Prevention of free fatty acid-induced hepatic lipotoxicity by carnitine via reversal of mitochondrial dysfunction. Liver Int 2011, 31:1315-1324.
35. Romano M., Vacante M., Cristaldi E., Colonna V., Gargante M.P., Cammalleri L., et al. L-carnitine treatment reduces steatosis in patients with chronic hepatitis C treated with alpha-interferon and ribavirin. Dig Dis Sci 2008, 53:1114-1121.
36. Xia Y., Li Q., Zhong W., Dong J., Wang Z., Wang C. L-carnitine ameliorated fatty liver in high-calorie diet/STZ-induced type 2 diabetic mice by improving mitochondrial function. Diabetol Metab Syndr 2011, 3:31.
37. Kathirvel E., Morgan K., French S.W., Morgan T.R. Overexpression of liver-specific cytochrome P4502E1 impairs hepatic insulin signaling in a transgenic mouse model of nonalcoholic fatty liver disease. Eur J Gastroenterol Hepatol 2009, 21:973-983.
38. Iossa S., Mollica M.P., Lionetti L., Crescenzo R., Botta M., Barletta A., et al. Acetyl-L-carnitine supplementation differently influences nutrient partitioning, serum leptin concentration and skeletal muscle mitochondrial respiration in young and old rats. J Nutr 2002, 132:636-642.
39. Virmani A., Gaetani F., Binienda Z., Xu A., Duhart H., Ali S.F. Role of mitochondrial dysfunction in neurotoxicity of MPP+: partial protection of PC12 cells by acetyl-L-carnitine. Ann N Y Acad Sci 2004, 1025:267-273.
40. Hota K.B., Hota S.K., Chaurasia O.P., Singh S.B. Acetyl-L-carnitine-mediated neuroprotection during hypoxia is attributed to ERK1/2-Nrf2-regulated mitochondrial biosynthesis. Hippocampus 2012, 22:723-736.
41. Cassano P., Sciancalepore A.G., Pesce V., Fluck M., Hoppeler H., Calvani M., et al. Acetyl-L-carnitine feeding to unloaded rats triggers in soleus muscle the coordinated expression of genes involved in mitochondrial biogenesis. Biochim Biophys Acta 2006, 1757:1421-1428.
42. Bagetta V., Barone I., Ghiglieri V., Di Filippo M., Sgobio C., Bernardi G., et al. Acetyl-L-carnitine selectively prevents post-ischemic LTP via a possible action on mitochondrial energy metabolism. Neuropharmacology 2008, 55:223-229.
43. Power R.A., Hulver M.W., Zhang J.Y., Dubois J., Marchand R.M., Ilkayeva O., et al. Carnitine revisited: potential use as adjunctive treatment in diabetes. Diabetologia 2007, 50:824-832.